Клиническая фармакология форадила (формотерола фумарат)

1. Цой А.Н., Архипов В.В. Клиническая фармакология современных стимуляторов β2-адренергических рецепторов. Клин, фармакол. и тер. 2000; 9 (5): 40-47.

2. Anderson G.P., Linden A., Rabe K.F. Why are long-acting betaadreoceptor agonists long-acting? Eur. Respir. J. 1994; 7: 569-578.

3. Anderson G.P. Formoterol: pharmacology, molecular basis of agonism and mechanism of long duration of a highly potent and selectivep β2-adrenoceptor agonist bronchodilator. Life Sci. 1992; 52: 2145-2160.

4. Aziz L., Wilson A.M., Lipwoth B.J. Effect of form oterol (FM) and Budesonide (BUD) alone or in combination (FM + BUD) on in flammatory markers in asthmatic adults (abstract). Eur. Respir. J. 1999; 14 (suppl. 30): 423 s.

5. Aziz I., Dempsey O.J., Sims E.I. et al. In vivo effect of albuterol on metacholine contracted bronchi in the presence of salmeterol and formoterol (abstract). Ibid. 529s.

6. Arvidsson P., Larsson S., Lofdahl G.G. et al. Inhaled formoterol during one year in asthma: a comparison with salbutamol. Ibid. 1991; 4: 1168-1173.

7. Barnes P.J. Beta-adrenergic receptors and their regulation. Am. J. Respir. Crit. Care Med. 1995; 152: 838-860.

8. Barnes P.J. Effects of 2-agonists and steroids on β2-adrenoceptors. Eur. Respir. Rev. 1998; 8 (55): 210-215.

9. Bartow R.A., Brogden R.N. Formoterol. An update of its pharmacological and therapeutic efficacy in the management of asthma. Drugs 1998; 55 (2): 303-322.

10. Brodde O.E., Home U., Egerzegi S. et al. Effects of prednisolone on β2-adrenoceptors in asthma tic patients receiving β2-bronchodilators. Eur. J.Clin. Pharmacol. 1988; 34: 145-150.

11. Burgess C., Ayson М., Rajasingham S. et al. The cardio vascular and metabolic effects of increasing doses of form oterol in patients with asthma (abstract). Eur. Respir. J. 1994; 7 (suppl.): 18.

12. Butter J.J., Vanden Berg B.T.J., Portier E.R.J.G . et al. Determination by HPLC with electrochemical detection of formoterol enantiomers in urine of healthy human subjects after single dose racematic in halations (abstract). Pharm. Wld Sci. 1995; 26 (suppl. 17): D6.

13. Centanni S. et al. Onset of action of single doses of formoterol administered via Turbuhaler (F). in patients with partially reversible COPD (abstract). Eur. Respir. J. 2000; 16 (suppl. 31): 275s.

14. Corvaja E., Giacobbe C., Girbino G. Bronchial response to salbutamol versus formoterol assessed by respiratory im pedance (abstract). Allergy 1996; 51 (suppl. 70): 79.

15. Dahl R., Earnshaw J.S., Palmer J.B.D. Salmeterol: a four wek study of along-acting beta-adrenoceptor agonist for the treatment of reversible airways disease. Eur. Respir. Dis. 1991; 4: 1178-1184.

16. Dahl R. et al. The cardiac safety profile of form oterol dry powder issimilar to placebo in patients with COPD (abstract). Eur. Respir. J. 2000; 16 (suppl. 31): 51s.

17. Derks M.G.M., van den Berg B.T.J., van Zeet J.S. et al. Pharmacokinetics/pharmacodynamics of inhaled formoterol (abstract). Neth. J. Med. 1995; 46: A 54.

18. Grove A., Lipworth B.J. Evalution of the β2-adrenoceptor agonist/antagonist activity of formoterol and salmeterol. Thorax 1996; 51: 54-58.

19. Grove A., Lipworth B.J. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 1995; 346: 201-206.

20. Johnson M. The β-adrenoceptor. Am. J. Respir. Crit. Care Med. 1998; 158 (5, pt 3): 146S-153S.

21. Johnson М., Coleman R.A. Mechanisms of action of β2-adrenoceptor agonists. In: Busse W.W., Holgate S.T. (eds). Asthma and Rhinits. Cam bridge: B lackw ell; 1995. 1278-1295.

22. Jones S.L. et al. Bronchodilator tolerance during acute bronchoconstriction in patients taking inhaled formoterol (abstract). Eur. Respir. J. 2000; 16 (suppl. 31): 96s.

23. Levitzki A., Marbach I., Bar-Sinai A. The signal transduction between β-receptors and adenylcyclase. Life Sci. 1993; 52 (26): 2093-2100.

24. Lipworth B.J. Treatment of acute asthma. Lancet 1997; 350 (suppl. II): 18-23.

25. Lofdahl C.G., Suedmyr N. Formoterol fumarate, a new β2-adrenoceptor agonist. Acute studies of selectivity and duration of effect after inhaled and oral administration. Allergy 1989; 44: 264-271.

26. Lotvall J. et al. Similar bronchodilation with formoterol delivered by aerolizer or turbuhaler. Can. Respir. J. 1999; 6 (5): 412-416.

27. Mak J.C.W., Nishikawa S., Shirasaki S. Protective effects of a glucocorticoid on down-regulation on pulm onary β2-adrenergic receptors. J. Clin. Invest. 1995; 96: 99-106.

28. Nishikawa D.M., Mak J.C.W., Barnes P.J. Effect of short and long-acting β2-agonists on pulmonary β2-adrenoceptor expression in human lung. Eur. J. Pharmacol. 1996; 318: 123-130.

29. O'Connor B.J., Aikman S.L., Barnes P.J. Tolerance to the nonbronchodilator effects of inhaled β2-agonists in asthma. N. Engl. J. Med. 1992; 327: 1204-1208.

30. Palmqvist M., Balder B., Lonhagen O. et al. Late asthmatic reaction decreased after pretreatment with salbutamol and formoterol, a new long-acting beta 2-agonist. J. Allergy Clin. Immunol. 1992; 89: 844-849.

31. Patseli-Troger K., Dietzel U., Schmidt E.W. Variability of onset and duration of effect of salmeterol and formoterol in patients with moderate and severe stable asthma (abstract). Eur. Respir. J. 1999; 14 (su p p l. 30): 328s.

32. Rabe K. et al. Comparisson of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am. Rev. Respir. Dis. 1993; 17 (pt1): 1436-1441.

33. Roth M. et al. The β2-agonist formoterol activates the glucocorticoid receptor in vivo (abstract). Eur. Respir. J. 2000; 16 (suppl. 31): 437s.

34. Sachse C., Brockmoller J., Bauer S. et al. Cytochrome p4502D6 variants in a Caucasian population: allelefrequencies and phenotypic consequences. Am. J. Hum. Genet. 1997; 60: 284-295.

35. Tan K.S., Grove A., McLean A. et al. Systemic corticosteroid rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Am. J. Respir. Crit. Care Med. 1997; 156; 28-35.

36. Tsoy A.N., Cheltzov V.V., Zaseyeva O.V. et al. Formoterol and terbutaline aerosols in nocturnal asthma (abstract). Eur. Respir. J. 1990; suppl. 10: 418s.

37. Vandenberg B.T.J., Smeets J.J., Vanboxtel C.J. et al. Evalution of different doses of formoterol from a newly developed powder inhalation device in asthmatic patients. Fundam. Clin. P harm acol. 1995; 9 (6): 593-603.

38. Van Shayck C.P. Do long-acting β2-adrenergic agonists deserve a different place in guidelines for the treatment of asthma and COPD. Eur. Respir. Rev. 2000; 15 (4): 531-534.

39. Wallin A., Sandstrom Т., Rosenhall L. Time course and duration of bronchodilation with formoterol dry powder in patients with stable asthma. Thorax 1993; 48: 611-614.

40. Yates D.H., Sussman H.S., Shaw M.J. et al. Regular formoterol treatment in mild asthma: effect on bronchial responsiveness and after treatment. Am. J. Respir. Crit. Care Med . 1995; 152: 1170-1174.

41. Yates D.H., Charitonov S.A., Barnes P.J. An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled β2-agonist. Am. J. Respir. C rit. Care Med. 1996; 154: 1603-1607.